#1Dimerix Immediate Release DIMERIX INVESTOR CALL & PRESENTATION MELBOURNE, Australia, 1 March 2022: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company invites shareholders to attend its investor webinar held today at 11am (AEDT) 1 March 2022. The webinar will cover Dimerix' activities, including the announcement regarding the changes to the REMAP-CAP COVID-19 study. Interested parties can register for the webinar using this link: https://zoom.us/webinar/register/WN_q1mnHbYTStClbQ_ClejUwg An investor presentation is attached to this announcement. Participants may submit questions during registration or during the session. For further information, please visit our website at www.dimerix.com or contact: Dr Nina Webster Dimerix Limited Chief Executive Officer & Managing Director Tel: +61 1300 813 321 E: [email protected] Follow us on LinkedIn and Twitter Rudi Michelson Monsoon Communications Tel: +61 3 9620 3333 Mob: +61 (0)411 402 737 E: [email protected] Authorised for lodgement by the Board of the Company -END- About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology. About DMX-200 DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease¹. DMX-200 is protected by granted patents in various territories until 2032, with additional applications submitted that may extend the protection to 2042 if granted. DMX-200 has demonstrated encouraging data that could provide meaningful clinical outcomes for patients with kidney disease across 4 clinical studies to date¹. DMX-200 is also under investigation as a potential treatment for patients with COVID-19 in two separate studies: REMAP-CAP and CLARITY 2.0. References 1 ASX releases: 12Jul17, 180ct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21 Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. [email protected]#2OUR KIDNEYS AFFECTED BY FSGS?. - LET'S WORK TOGETHER Dimerix (ASX:DXB) Investor Briefing 01 March 2022 Authorised for lodgment by the Board of the Company#3Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation. Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection. Dimerix 2#4About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease Advancing three Phase 3 clinical studies Patent protected products with commercial manufacturing established Dimerix Demonstrated clinical efficacy¹; drug well understood, with strong safety profile¹ Strong outlook with potential for significant value² upside 1 ASX releases: 12Jul17, 180ct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan 21, 24Mar21, 03Jun21, 07Jun21, 19Jul21 3 2 See slides 8 and 13 for market potential#5Corporate overview ASX $ $ A Ticker Symbol Cash Balance (31Dec21) Market Capitalisation Share price Total ordinary shares on issue Average volume Top 20 Shareholders own ASX:DXB A$16.3 million ~A$58 million ~A$0.18 Share price Chart generated on 24/2/2022 at 9:34 am dxb March 2021 Volume April May June July August September October November December January 2022 February Dimerix 320,873,666 1,177,054 Top shareholders 35% Position Holder Name Holding % IC 0.40 1 Mr Peter Meurs 44,179,309 13.8% 0.35 2 0.30 Merchant Group & Nominees 17,925,000 5.6% 3 Mr Andrew & Mrs Melinda Coates 8,100,000 2.5% 0.25 4 0.20 Bavaria Bay Pty Ltd 7,316,992 2.3% LO 5 Yodambao Pty Ltd 6,362,603 2.0% 6 Solequest Pty Ltd & Nominees 3,387,302 1.1% 30M 7 20M Pfleger Family A/C & Nominees 3,137,874 1.0% 10M 8 Tamer Yigit Property Group Pty Ltd 3,101,343 1.0% 9 Rubi Holdings Pty Ltd 2,500,000 0.8% 10 Jampaso Pty Ltd and Nominees 2,377,355 0.7% TOTAL (TOP 10) 98,387,778 30.7% 4#6Development pipeline Program Indication Focal Segmental Glomerular Sclerosis (FSGS) DMX-200 Diabetic Kidney Disease Late COVID pneumonia – REMAP-CAP Preclinical Phase 1 Phase 2 Phase 3 Key milestones Phase 2a demonstrated encouraging efficacy & safety¹; Phase 3 underway with regulatory &/or ethics authorisation in multiple countries², recruitment of 1st patients planned Q1 22, 1st interim data anticipated H1 233 Phase 2 demonstrated promising efficacy and safety, planning of next study design underway Early COVID respiratory - CLARITY 2.0 DMX-700 Chronic Obstructive Pulmonary Disease (COPD) DMX-XXX Undisclosed (multiple) Recruitment underway across Europe4, initial data anticipated Q1 223 Recruitment underway across India 5, ethics approval in Australia, interim data from India anticipated Q1 223 Pre-clinical studies underway to support entry into clinical studies; data anticipated Q2 22 Additional target opportunities identified using Receptor-HIT; preliminary exploratory work underway Dimerix 1 ASX releases: 12Jul17, 180ct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21 2 ASX releases: 21Oct21, 01Feb22 (Australia, Denmark); + Taiwan approved on 08Feb22 3 Subject to recruitment 4 ASX release: 23Apr21, 16Dec21 5 ASX release: 11Jan22 6 ASX release: 23Dec21 5#7COVID-19 Respiratory Complications#8Potential benefits of DMX-200 prolen coupled receptors (GPCR) Antiviral medications: Typically effective at preventing damage caused by a virus when administered within 3-5 days of infection¹ when many are asymptomatic DMX-200: Does not rely on early inhibition of viral replication DMX-200 aims to prevent damaging immune response regardless of vaccination or antiviral treatment DMX-200: May be beneficial for patients with a wide range of respiratory diseases in addition to COVID² Antivirals are usually very specific for a virus and sometimes even the particular strain of the virus¹ Dimerix 22 1. 2. Brown L et al (2021) Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial: DOI: 10.1186/s13063-021-05139-27 Based on Szabo, et al., 2020; Merad, et al., 2020; Xiong, et al, 2020; Wu, et al., 2021; Chen, et al., 2009; Yong, et al., 2016#9Two Phase 3 studies in COVID-19 patients Patients were randomised patients to receive one of: 1. 2. Angiotensin receptor blocker (ARB) alone Angiotensin converting enzyme (ACE) inhibitor alone ARB simultaneously with DMX-200 No RAS inhibitor (no placebo) 3. REMAP CAP 4. J NHMRC Clinical Trials Centre BB THE UNIVERSITY OF SYDNEY . REMAP-CAP: COVID-19 pneumonia in ICU >779 patients recruited to the study domain WHO endorsed study Primary endpoint = 21 day mortality Funded by European Union through H2020 "Rapid European COVID-19 Emergency Research response" (RECOVER) project CLARITY 2.0: COVID-19 respiratory complications Recruiting >600 patients in India and Australia Primary endpoint = 14 day WHO Clinical Health Score Run through the NHMRC Clinical trials centre and the University of Sydney Dimerix Secondary endpoint: recovery and quality of life post hospitalisation (long-COVID assessment) Initial study data anticipated Q1 2022 8#10Kidney Disease Development Overview#11FSGS phase 3 study design A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB ACTION3 FSGS CLINICAL STUDY Dimerix ARB stabilisation weeks -6 -1 0 Recruited Treatment period 35 All patients will remain on ARB treatment at a stable and maximal tolerated dose Randomisation • Stabilise ARB and any other medications (as appropriate) • 1st dose DMX-200 Placebo T I 1st interim analysis; n=72, proteinuria at week 35 ⚫2nd analysis Accelerated Approval endpoint; n=144* (72 1st analysis + 72), proteinuria + eGFR at week 35 104 • Final analysis (n=286) eGFR slope at week 104 ARB: Angiotensin Receptor Blocker *Subject to recruitment rate and conditional power 10 Accelerated endpoint: Marketing approval for serious conditions that fill an unmet medical need based on a surrogate or an intermediate clinical endpoint#12FSGS phase 3 study locations ACTION3 FSGS CLINICAL STUDY Global study with ~70 sites in 12 countries: Country Australia Argentina Brazil Regulatory and/or ethics approval to proceed A randomised, double-blind, multi-centre, placebo- controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB Denmark France Hong Kong New Zealand South Korea Spain Taiwan UK USA Dimerix 11#13Mi Endpoint . . Dow IT C Corporate Outlook#14Potential value driving events 2021 2022 clinical DMX-200 demonstrated encouraging efficacy and strong safety profile across multiple Phase 2 renal clinical studies Consistent advice received from FDA, EMA and UK MHRA on FSGS Phase 3 study design Orphan Drug Designation/accelerated approval pathway granted by US FDA, EU EMA and UK MHRA for FSGS Two independent Phase 3 clinical studies underway in patients with COVID-19 respiratory complications DMX-200 manufacturing process optimised to improve commercial scalability and global logistics DMX-700 in COPD progressed further towards clinical development Expansion of IP portfolio Strong financial position Dimerix FSGS ethics approval and clinical site initiations FSGS Phase 3 study recruitment and first patient first dose REMAP-CAP Phase 3 COVID-19 study recruitment and top line data CLARITY 2.0 Phase 3 COVID-19 study recruitment and top line data DMX-700 for Chronic Obstructive Pulmonary Disease progression towards clinical study Diabetic kidney disease clinical study design and next steps Further expansion of IP portfolio FSGS Phase 3 study Part 1 analysis and progression to Part 2 13#15Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Advancing three Phase 3 opportunities Well positioned to deliver against strategic plan Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. [email protected] ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.